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Background
Heart failure (HF) remains a therapeutic challenge with
high morbidity and mortality and frequent hospitaliza-
tions. Activators of guanylyl cyclase (GC) A and/or GC-
B such as naturally occurring or designer natriuretic
peptides (NPs) are promising candidates for chronic
drug therapy; however, parenteral administration is
required. Pumps or subcutaneous administration similar
to those used for insulin therapy are an attractive means
of enabling chronic peptide delivery. Cenderitide (also
known as CD-NP) is a Mayo designed chimeric NP con-
sisting of C-type NP with the C-terminus of Dendroas-
pis NP currently in clinical development for the
treatment of HF. Cenderitide is a dual agonist at both
GC-A and GC-B and is relatively resistant to enzymatic
degradation. This study was designed to assess the bioa-
vailability of cenderitide when given as a subcutaneous
(SQ) bolus as compared to an intravenous (IV) bolus.
Hypothesis
We hypothesized that given cenderitide’s relative resis-
tance to enzymatic degradation it would have good SQ
bioavailability as compared to IV administration.
Methods
Ports were implanted into the femoral artery of four
healthy mongrel dogs (weight 21-25 kg). After recovery
from surgery dogs underwent two studies on two days
with one day in between. On study days, animals were
placed into a table top sling and the arterial port was
connected via a Huber needle to a pressure gauge to
allow measurement of mean arterial pressure (MAP)
and heart rate and arterial blood sampling. After base-
line measurements and blood sampling, animals received
either an IV bolus (10 µg/kg) or, on the other study
date, a SQ bolus (40 µg/kg) of cenderitide. Blood sam-
ples and MAP measurements were collected for 300
minutes post bolus administration. Two animals started
with an IV bolus, the two other with a SQ bolus. Cen-
deritide levels were measured using a CNP radioimmu-
noassay that crossreacts with cenderitide. Cyclic GMP
was measured by radioimmunoassay. *p<0.05 compared
to respective baseline values.
Results
After IV bolus administration, CNP levels were signifi-
cantly increased compared to baseline from 0.5’ to 10’
after bolus administration (from 7±2 at baseline to a
maximum of 8843±3259 pg/mL after 0.5’). Cyclic GMP
levels were increased from 2’ to 90’ after IV bolus (from
10±2 to a maximum of 90±7 pmol/mL after 20’). MAP
was significantly decreased from 20’ to 60’ post IV bolus
(from baseline 118±6 to a minimum of 92±15 mmHg
after 45’). After SQ bolus administration, CNP levels
were significantly increased compared to baseline from
10’ to 90’ after bolus administration (from 9±2 to a
maximum of 2200±393 pg/mL after 40’). Cyclic GMP
levels were increased from 20’ to 180’ after bolus (from
10±3 to a maximum of 94±6 pmol/mL after 60’). MAP
was significantly decreased from 35’ to 300’ post bolus
(from baseline 124±7 to a minimum of 91±6 mmHg
after 300’). Based on the areas under the curve and
accounting for dose, bioavailability of cenderitide
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IV bolus administration.
Conclusion
Cenderitide, a dual GC-A/GC-B agonist with relatively
high resistance to enzymatic degradation, had good
bioavailability when administered as a SQ bolus as com-
pared to IV administration. SQ administration was asso-
ciated with a sustained increase in cenderitide
immunoreactivity (up to 90’), activation of cGMP (up to
180’ post bolus) and decrease in MAP (up to 300’).
These findings provide important and promising infor-
mation supporting the further development of cenderi-
tide as a therapeutic for chronic SQ delivery.
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